Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Geleta has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modeling women’s reported under-five child mortality in Ethiopia: a comparative evaluation of zero-inflated and hurdle regression models

    by Buzuneh Tasfa Marine, Abraham Lomboro Dimore, Addis Birhanu, Amanuel Mengstu Merera, Temesgen Soboka, Dawit Regassa, Warkitu Sileshi Ensermu, Teklemariam Ergat Yarinbab, Fira Abamech, Yibeltal Siraneh, et al.

  • Open Access

    Excessive daytime sleepiness and associated factors among commercial vehicle drivers in Jimma Zone, Southwest Ethiopia

    by Hiwot Berhanu, Wondu Reta, Moyeta Bariso, Elias Mulat, Kumale Tolosa, Zeleke Mekonnen, Daniel Geleta

  • Open Access

    Prevalence, clinical features and determinants of cutaneous leishmaniasis in central Ethiopia

    by Tagesech Yohannes, Getenet Beyene, Daniel Geleta, Zeleke Mekonnen

    Cutaneous Leishmaniasis (CL) represents the prevalent form of leishmaniasis affecting the most disadvantaged communities globally. It presents a notable pu

  • Open Access

    Emerging Multidrug‐Resistant Bacteria in Indonesian Neonatal Patients: Prevalence and Antimicrobial Resistance Profiles From Clinical Samples

    by Muhammad Evy Prastiyanto, Afifah Khairunnisa, Andri Sukeksi, Tulus Ariyadi, Rizal Maarif Rukmana, Budi Santosa, Daniel Geleta

    Background: Neonatal sepsis poses a serious health challenge, especially with the increasing prevalence of multidrug‐resistant (MDR) bacteria among Indonesian neonates. This study examines the occurrence of MDR bacteria in clinical samples from neonates and analyzes their resistance patterns to enhance treatment strategies. Methods: From January 2022 to December 2024, a total of 223 bacterial isolates were gathered from neonatal patients with infections at Kanjeng Raden Mas Tumenggung Wongsonegoro Hospital in Semarang, Indonesia. The identification process commenced with Gram staining and assessment of colony morphology preceded by antibiotic susceptibility testing utilizing the VITEK2 Compact systems. Results: The study findings revealed a notable prevalence of MDR infections. Fecal samples accounted for 29.15% of the samples analyzed, with 63.1% exhibiting MDR characteristics. Blood samples, representing 24.66% of the samples, displayed a concerning MDR rate of 83.6%. Similarly, urine samples (24.66%) showed a MDR rate of 50.9%, while sputum samples (10.76%) presented a striking MDR classification of 91.7%. Key MDR rates were identified in Escherichia coli (45.6%), Staphylococcus spp. (70.4%), Klebsiella pneumoniae (71.9%), Acinetobacter spp. (63.6%), and Pseudomonas aeruginosa (100%). The overall prevalence of MDR infections was calculated at 66.40%, with significant resistance observed towards ampicillin (over 80%) in gram‐negative bacteria and benzylpenicillin (over 90%) in gram‐positive bacteria, particularly Staphylococcus spp. Conclusion: The findings underscore the urgent need for effective strategies to combat MDR infections in healthcare settings, emphasizing enhanced antibiotic management, tailored treatment protocols, and a more holistic and systematically structured research strategy for neonatal units in Indonesia.

  • Open Access

    A Cross‐Sectional Study of Extended‐Spectrum β ‐Lactamase–Producing Escherichia coli Isolated From Clinical Samples: Single‐Center Investigation in Indonesia

    by Fitrotin Azizah, Dita Artanti, Yety Eka Sispita Sari, Anindita Riesti Retno Arimurti, Arya Iswara, Afifah Khairunnisa, Muhammad Evy Prastiyanto, Daniel Geleta

    The emergence of extended‐spectrum beta‐lactamase–producing Escherichia coli (ESBL‐producing E. coli ) is a significant public health concern, particularly in developing countries like Indonesia, where reports on the prevalence and characteristics of these resistant strains are scarce. This lack of data hampers effective infection control and antibiotic stewardship efforts. This study is aimed at investigating the prevalence and assessing the antimicrobial susceptibility profiles of ESBL‐producing E. coli isolated from clinical samples of Indonesian patients, thereby contributing to an understanding of antibiotic resistance patterns in this region. A cross‐sectional study was conducted at RSUD dr. Adhyatma Hospital, Semarang, Indonesia, over 3 years (from January 2022 to December 2024). Clinical specimens were obtained from patients diagnosed with E. coli infections, and isolates were identified and assessed for antibiotic susceptibility utilizing the VITEK2 Compact system. Data were examined via the Fisher’s exact test. Out of 449 E. coli isolates, 199 (44.3%) were identified as ESBL, with the highest prevalence in pus (35.6%) and urine (27.2%). ESBL‐producing E. coli isolates demonstrated high sensitivity (above 90%) to amoxicillin–clavulanic acid, ceftazidime, ertapenem, meropenem, and tigecycline. Our study also underlined the higher prevalence of multidrug resistance (MDR) in ESBL compared to non‐ESBL. The results highlight the urgent need for enhanced surveillance and infection control measures in healthcare settings to combat the spread of ESBL‐producing E. coli . Healthcare professionals, including nurses and clinicians, must be aware of this resistance pattern to guide empirical treatment choices and improve patient outcomes in managing infections caused by these resistant strains.


  • Open Access

    Prevalence and pathogen profiles of bacteremia in neonates hospitalized for clinical Sepsis in Ethiopia: a systematic review and meta-analysis

    by Daniel Geleta, Gemeda Abebe, Tsion Tilahun, Hunde Ahmed, Netsanet Workneh, Getenet Beyene

    Bacteremia is prevalent in neonates, largely attributed to factors inherent in the neonatal period. However, the prevalence of proven bacteremia in Ethiopian neonates has not been previously synthesized. Accordingly, this systematic review and meta-analysis aimed to analyze the prevalence of bacteremia and pathogen profiles in neonates hospitalized for clinical sepsis in Ethiopia. This systematic review and meta-analysis followed the preferred reporting items for systematic review and meta-analysis (PRISMA) 2020. The literature search was conducted across five databases including PubMed, Google Scholar, Web of Science, Science Direct, and Research for Life spanning from January 2015 to July 2023. The search strategy used MeSH terms and involved screening titles and abstracts, reviewing full-text articles, and including only observational studies published in English within the specified timeframe. Data extraction and quality assessment were performed by three experienced reviewers using a validated data collection tool and the Joanna Briggs Institute quality assessment tool, respectively. The prevalence of neonatal bacteremia was determined through a random effects model, with heterogeneity among studies assessed using the Q statistic and the I2 statistic. Publication bias was evaluated using a funnel plot and Egger’s regression test, and STATA version 16.0 was used for all analysis at 95% confidence level. A meta-analysis of nine studies revealed a bacteremia prevalence of 40.0% (95% CI: 34.0–46.0%). Subgroup analysis indicated variations in prevalence based on regions and study designs, with Oromia at 44.0% (95% CI: 28.0, 61.0%) and Amhara at 39.0% (95% CI: 27.0, 51.0%). Longitudinal studies exhibited a higher prevalence (47.0%, 95% CI: 27.0–68.0%) compared to cross-sectional designs (38.0%, 95% CI: 32.0–44.0%). Gram-negative bacteria were identified as the predominant etiological agents, representing 59.5% (95% CI: 56.8–62.3%) of cases. Among the bacterial species, Staphylococcus aureus emerged as the most prevalent (20.0%, 95% CI: 18.0%, 22.0%), followed by coagulase-negative staphylococci and Klebsiella pneumoniae, each contributing to 17.0% (95% CI: 15.0%, 20.0%) of bacteremia cases. The study revealed a significant high prevalence of bacteremia, with differences noted across regions and study designs. Key pathogens identified were Staphylococcus aureus, Klebsiella pneumoniae and coagulase-negative staphylococci. It is advisable to implement surveillance systems, targeted prevention strategies, diagnostic stewardship, and further research on regional variations and bacterial profiles to effectively enhance the ominous future.


  • Open Access

    Molecular and clinical insights into extended-spectrum β-lactamase genes of Klebsiella pneumoniae isolated from neonatal sepsis in Ethiopia

    by Daniel Geleta, Gemeda Abebe, Tsion Tilahun, Alemseged Abdissa, Adane Mihret, Raffaele Joseph Cataldo, Netsanet Workneh, Abel Abera Negash, Getenet Beyene

    Klebsiella bacterial strains harboring Extended-Spectrum Beta-Lactamase (ESBL) enzymes are the primary culprits behind neonatal sepsis globally. These strains significantly impact clinical outcomes due to their multi-drug resistance patterns in local healthcare settings. In response to this spiraling threat, we studied the prevalence and clinical implications of ESBL-encoding genes in neonates hospitalized with confirmed sepsis. A correlational study was conducted on 51 neonates diagnosed with sepsis caused by ESBL-positive Klebsiella pneumoniae at Jimma Medical Center spanning from May 2022 to July 2023. Antimicrobial resistance profiles of the bacterial isolates were determined using the Kirby-Bauer diffusion test, while multiplex polymerase chain reaction (mPCR) techniques were employed to identify resistance genes. The correlation between resistance genes and treatment outcomes was analyzed using the phi coefficient (φ) with a significance level below 0.05. The data management was executed through the utilization of WHONET and STATA software platforms. The sample consisted of 26 (50.9%) male and the remaining 25 (49.1%) female neonates, with diverse clinical characteristics. All 51 Klebsiella pneumoniae isolates were 100% resistant to trimethoprim/sulfamethoxazole and ceftriaxone, but showed varying resistance profiles ranging from 30.8% to meropenem to 94.2% to ceftazidime. Notably, all isolates demonstrated multidrug resistance, with 23% of cases showing resistance to seven different antimicrobial classes. The most prevalent resistance genes identified were blaCTX−M (96.1%), blaTEM (94.1%), and blaSHV (88.2%). The majority of isolates (94.1%) carried at least two resistance genes, such as blaTEM and blaCTX (94.1%), blaTEM and blaSHV (86.2%), and blaCTX and blaSHV (86.2%). Notably, 84.3% of the bacteria harbored the trio of blaTEM, blaCTX, and blaSHV resistance genes, and only the presence of blaSHV in monogenic (φ = 0.4, P = 0.01) or the trio of blaTEM, blaCTX, and blaSHV genes (φ = 0.3, P = 0.02) showed positive correlation with neonatal mortality. We observed a significant prevalence of multidrug-resistant Klebsiella pneumoniae strains among neonates. Moreover, ESBL-resistance genes were widespread, with the blaSHV gene showing a correlation with increased neonatal mortality. These findings emphasize the urgent need for enhanced infection prevention measures, robust antimicrobial resistance surveillance, innovative treatment strategies, antibiotic stewardship initiatives, further research into resistance transfer mechanisms as well as hierarchical predictors of neonatal mortality. Not applicable.


  • Open Access

    Phenotypic bacterial epidemiology and antimicrobial resistance profiles in neonatal sepsis at Jimma medical center, Ethiopia: Insights from prospective study

    by Daniel Geleta, Gemeda Abebe, Tsion Tilahun, Didimos Gezahegn, Netsanet Workneh, Getenet Beyene

    Background: Epidemiological profiles and the rundown crisis of antimicrobial resistance from bacterial isolates in neonatal sepsis compel regular surveillance to enhance data-driven decision-making. Accordingly, this study aimed to assess the phenotypic epidemiology and antimicrobial resistance profiles of bacteria isolated from clinically suspected neonatal sepsis in Ethiopia. Methods: A total of 342 neonates suspected of clinical sepsis were randomly included in a prospective observational study conducted at the neonatal intensive care unit (NICU) of Jimma medical center (JMC) from May 2022 to July 2023. Blood samples were collected from each neonate and subjected to a culture test for identification of bacterial isolates and their antibiotic resistance profiles following the standardized guidelines. The laboratory results, along with relevant clinical data, were recorded using WHONET and analyzed using STATA software. Results: Out of the 342 blood samples that were analyzed, 138 samples (40.4%, 95% CI: 35.1–45.6, PKlebsiella pneumoniae (37.7%, 95% CI: 29.6–45.8), Coagulase-negative Staphylococci (CoNs) (20.3%, 95% CI: 13.6–27.0), and Acinetobacter species (11.6%, 95% CI: 6.0–17.1). Of the total cases, 43/72 (59.7%, 95% CI: 48.4–71.1, PKlebsiella pneumoniae displayed high resistance rates to trimethoprim-sulfamethoxazole (100%), ceftriaxone (100%), cefotaxime (98.1%), ceftazidime (90.4%), and gentamicin (84.6%). Acinetobacter species showed resistance to ampicillin (100%), cefotaxime (100%), trimethoprim-sulfamethoxazole (75%), ceftazidime (68.8%), chloramphenicol (68.8%), and ceftriaxone (68.8%). Likewise, CoNs displayed resistance to ampicillin (100%), penicillin (100%), cefotaxime (86.0%), gentamicin (57.2%), and oxacillin (32.2%). Multidrug resistance was observed in 88.4% (95% CI: 81.8–93.0) of isolates, with ESBL-producers significantly contributing (49.3%, 95% CI: 45.1–53.5). Furthermore, 23.0% (95% CI: 15.8–31.6) exhibited a prevalent resistance pattern to seven distinct antibiotic classes. Conclusion: The prevalence and mortality rates of neonatal sepsis were significantly high at JMC, with a notable surge in antibiotic and multidrug resistance among bacterial strains isolated from infected neonates, specifically ESBL-producers. These resistant strains have a significant impact on infection rates and resistance profiles, highlighting the requisite for enhanced diagnostic and antimicrobial stewardship, stringent infection control, and further molecular characterization of isolates to enhance neonatal survival.


    • 1 March 2024
      • Vol. 47  (1) , 1-14

    Mechanisms of Bacterial Drug Resistance with Special Emphasis on Phenotypic and Molecular Characterization of Extended Spectrum Beta-lactamase

    by Daniel Geleta, Gemeda Abebe, Bikila Alemu, Netsanet Workneh, Getenet Beyene

    Antibiotics are designed to effectively treat bacterial infections while minimizing harm to the human body. They work by targeting specific components of bacteria or by disrupting essential processes such as cell wall synthesis, membrane function, protein production, and metabolic pathways. However, the misuse and overuse of antibiotics have led to the emergence of drug resistance in humans, animals, and agriculture, contributing to the global spread of this problem. Drug resistance can be either innate or acquired, with acquired resistance involving changes in the bacterial chromosomes or transferable elements. Bacterial species employ various mechanisms of drug resistance, including modifying the antibiotic targets, inactivating the drug, reducing uptake or increasing efflux, overexpressing the target, utilizing alternative pathways, and forming biofilms. One significant concern in the realm of drug resistance revolves around the emergence and proliferation of extended-spectrum beta-lactamases (ESBLs), a gene that is found in most gram-negative bacteria, primarily carried by Escherichia coli and Klebsiella pneumoniae in healthcare settings. ESBL-mediated resistance poses challenges for diagnosis, treatment, infection control, and antibiotic stewardship. Accurate detection of ESBL genes is crucial, and phenotypic methods are commonly used for initial screening. However, these methods have limitations, and confirmatory molecular techniques such as PCR and DNA sequencing are employed to accurately identify ESBL genes. Despite the significant global concerns surrounding ESBLs, they have spread worldwide, mainly facilitated by healthcare settings, inappropriate antimicrobial use, and host susceptibility. Addressing this issue requires implementinitiatives, and research focused on developing new drugs. Furthermore, collaboration among the healthcare, public health, and research sectors is pivotal in effectively combating the escalating threat posed by ESBL-mediated resistance. Antibiotics have revolutionized medical care by effectively treating bacterial infections. However, the emergence of ESBL gene resistance poses a global challenge that requires an integrated approach to prevent a threatening future.